drugset
drugset / Trial / NCT03618160

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

NCT03618160 ↗

Phase 1 Terminated 42 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.

Timeline

Start
2018-08-06
Primary completion
2019-06-21
Completion
2019-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64565111 Unknown — Subcutaneous

Indications

No indication recorded.